CBD의 의학적 치료 효능

CBD의 의학적 치료 효능

CBD는 칸나비스에 있는 주요 칸나비노이드 중 하나입니다.
CBD is one of the major cannabinoids found in cannabis.

 

연구 결과에 따르면 CBD는 안전하고 효과적으로 다양한 치료 효능을 제공합니다.
Studies have shown it safely and effectively provides a plethora of therapeutic benefits.

 

CBD 개요  
OVERVIEW OF CBD

 

칸나비스의 THC는 관심을 끌 수 있는 칸나비노이드이지만, CBD의 치료 효능에 대한 최근의 놀라운 연구 결과는 마침내 비-정신자극(non-psychoactive) 화합물에 빛을 비추고 있습니다.
While cannabis’ tetrahydrocannabinol (THC) is the cannabinoid that gets most of the attention, the relatively recent monumental findings on the therapeutic benefits of cannabidiol (CBD) are finally giving the non-psychoactive compound its due shine.

 

 

발견: CBD의 효능
FINDINGS: EFFECTS OF CBD

연구 결과에 따르면, CBD는 구역질 및 구토를 안전하고 효과적으로 감소시키고, 발작 활동을 억제하며, 정신병을 퇴치하고, 염증 질환을 고치고, 신경퇴행성 장애를 해결하며,  종양 및 암세포와 싸우며, 불안과 우울 장애를 치료합니다 (Fernandez-Ruiz 등, 2013).
Studies have shown that CBD safely and effectively reduces nausea and vomiting, suppresses seizure activity, combats psychosis disorders, contests inflammatory disorders, counters neurodegenerative disorders, fights tumor and cancer cells, and battles anxiety and depression disorders (Fernandez-Ruiz, et al., 2013).

 이러한 주목할 만한 효과로 인해 CBD는 신경염증, 뇌전증, 산화손상, 구토 및 메스꺼움, 불안증, 조현병에 대한 치료 방법으로서의 흥미진진한 잠재력을 보여줍니다 (Fernandez-Ruiz 등 2013).
Because of these notable effects, CBD shows exciting potential as a treatment option for neuroinflammation disorders, epilepsy, oxidative injury, vomiting and nausea, and anxiety and schizophrenia (Fernandez-Ruiz, et al., 2013).

 

알츠하이머병 Alzheimer’s Disease

 

CBD는 소교신경(microglial) 활성화를 차단하여, 신경보호를 함으로써 알츠하이머병의 진행을 제한합니다 (Martin-Moreno 등 2011) (Ramirez 등 2005) (Campbell & Gowran, 2007).
CBD limits the progression of Alzheimer’s disease by blocking microglial activation and thus providing neuroprotection (Martin-Moreno, et al., 2011) (Ramirez, et al., 2005) (Campbell & Gowran, 2007).

 CBD가 제공하는 신경보호, 항산화, 항암 효과의 조합은 알츠하이머병과 관련된 산화 스트레스를 감소시킵니다(Iuvone 등 2004).
The combination of neuroprotective, anti-oxidative and anti-apoptotic effects provided by CBD decreases the oxidative stress associated with Alzheimer’s disease. (Iuvone, et al., 2004).

 

칸나비노이드 전문

www.dopza.com  

돕자몰

 

 

루게릭병 (ALS)
Amytotraphic Lateral Sclerosis (ALS)

 

CBD는 ALS의 발병을 유의하게 늦출 수 있습니다(Weydt 등 2005).
CBD can significantly slow the onset of ALS (Weydt, et al., 2005).

 

또한 일반적으로 ALS와 관련된 통증, 식욕상실, 우울증, 수면장애, 경련, 침흘림을 줄일 수 있습니다(Amtmann 등 2004) (Carter, Abood, Aggarwal & Weiss, 2010).
In addition, it can help reduce the pain, appetite loss, depression, sleeping problems, spasticity and drooling that can are commonly associated with ALS (Amtmann, et al., 2004) (Carter, Abood, Aggarwal & Weiss, 2010).

 

 

불안증  Anxiety Disorder

 

CBD는 불안증을 줄이기 위해 뇌의 변연계 (limbic)와 주위변연계 (paralimbic) 부위에 영향을 주고, 주관적 불안을 현저히 감소시키는 능력을 보여주었습니다(Crippa 등 2011).
CBD has effects on the limbic and paralimbic areas of the brain to reduce anxiety and has demonstrated the ability to significantly decrease subjective anxiety (Crippa, et al., 2011).

 

또한 사회불안장애(SAD)를 가진 사람들의 대중연설 관련 불안, 인지장애, 불편을 현저히 감소시키는 것으로 나타났습니다 (Bergamaschi 등 2011).
It’s also been shown to significantly reduce the anxiety, cognitive impairment and discomfort associated with public speaking in individuals with Generalized Social Anxiety Disorder (SAD) (Bergamaschi, et al., 2011).

 

관절염 Arthritis

 

CBD는 관절염을 예방하는 항-염증 효과와 강력한 항-관절염 효과로 관절염 진행을 제한합니다 (Malfait 등 2000).
With its anti-inflammatory benefits and potent anti-arthritic effects that protect joints, CBD limits the progression of arthritis (Malfait, et al., 2000).

 

뼈 건강 Bone Health

 

CBD는 뼈를 붙잡고 있는 뼈의 결합 조직에 있는 단백질인 콜라겐의 성숙을 향상시켜 뼈의 강도와 치유 과정을 크게 향상시킵니다(Kogan 등 2015).
CBD enhances the maturation of collagen, the protein in the bone’s connective tissue that holds the bone together, which in turn significantly improves the strength and the healing process of bones (Kogan, et al., 2015).

 

칸나비노이드 전문

www.dopza.com  

돕자몰

 

암 Cancer

 

CBD는 동물 모델에서 유방, 폐, 전립선, 결장 암의 진행을 억제하여 사람 피험자의 암세포 사망을 매개하는 데에도 효과적일 수 있다고 제안했습니다(McAllister, Soroceanu & Desprez, 2015) (Orellana-Serradell 등 2015) (Ligresti 등 2006).
CBD inhibits the progression of cancers located in the breast, lung, prostate and colon in animal models, which suggests that it could also be effective at mediating cancer cell death in human subjects (McAllister, Soroceanu & Desprez, 2015) (Orellana-Serradell, et al., 2015) (Ligresti, et al., 2006)

 유방암 세포의 증식과 침입을 억제하고, 유방암 세포의 유전자 발현을 감소시켜 종양의 공격성을 낮추고 크기를 현저하게 줄이는 것으로 나타났습니다(McAllister 등 2007).
It’s been shown to inhibit human breast cancer cell proliferation and invasion, and decrease the gene expression in breast cancer cells, thus lowering tumor aggressiveness and significantly reducing its size (McAllister, et al., 2007).

 CBD산(CBDA)은 침윤성 뇌암 세포를 하향 조절하여 이들의 성장을 억제하는 능력을 보였습니다(Takeda 등 2014) (McAllister 등 2011).
CBD acid (CBDA) has shown the capability of down-regulating invasive human brain cancer cells and therefore preventing their growth (Takeda, et al., 2014) (McAllister, et al., 2011).

 

 

심혈관 질환 Cardiovascular Disease

 

CBD는 심혈관 질환 치료에 집합적으로 치료 효과를 제공하는 심근기능 장애, 심장섬유증, 산화-질산 스트레스, 염증, 세포사멸, 상호연관된 신호전달경로를 감소시킵니다(Rajesh 등 2010).
CBD reduces myocardial dysfunction, cardiac fibrosis, oxidative-nitrative stress, inflammation, cell death, and interrelated signaling pathways, which collectively offers therapeutic benefits in the treatment of cardiovascular diseases (Rajesh, et al., 2010).

 또한, 심장발작 직후에 CBD를 투여하면 경색 크기 및 심근염증을 감소시켜 심근 허혈에 대한 치료제로서의 가능성을 보여 주었습니다(Durst 등 2007).
In addition, administering CBD shortly after a heart attack has been shown to reduce infarct size and myocardial inflammation, thus showing potential as a treatment for myocardial ischemia (Durst, et al., 2007).

 

 

경변증 (간질환)
Cirrhosis (Liver Disease)

 

연구에 따르면 CBD는 간 성상 세포 (HSC)의 사망을 돕는 방법을 통하여, 간경변 진행과 싸우는데, 간경변은 과도한 콜라겐을 번식하고 생성하여 간에 흉터를 축적시킵니다(Lim, Devi & Rozenfeld, 2011).
Studies suggest that CBD helps combat cirrhosis progression by assisting in the death of hepatic stellate cells (HSCs), which proliferate and produce excess collagen, causing the accumulation of scarring on the liver (Lim, Devi & Rozenfeld, 2011).

 CBD는 또한 간 기능 부전을 겪는 쥐에서 간 기능을 회복시키는 것으로 밝혀졌습니다 (Abraham 등 2011).
CBD has also been shown to restore liver function in mice experiencing liver failure (Abraham, et al., 2011)

 또한 CBD는 주요 염증 경로와 산화/질화 조직 손상의 힘을 줄임으로써, 간경화에서 조직 손상의 중추적 메커니즘인 허혈 재관류를 예방합니다 (Mukhopadhyay, Rajesh & Pacher, 2011).
In addition, CBD provide protection against ischemia reperfusion, the pivotal mechanism of tissue damage in cirrhosis, by reducing the force of key inflammatory pathways and oxidative/nitrative tissue injury (Mukhopadhyay, Rajesh & Pacher, 2011).

 

크론병(과민성대장증후군)
Crohn’s Disease (Irritable Bowel Syndrome)

 

CBD는 소화기 궤양의 항-염증을 지원합니다(Esposito 등 2013) (De Filippis 등 2011).
CBD supports anti-inflammation of the digestive track (Esposito, et al., 2013) (De Filippis, et al., 2011).

CBD는 질병으로 인한 친-염증 반응을 조절할 수 있습니다 (De Filippis 등 2011).
CBD is able to control the pro-inflammatory response caused by the disease (De Filippis, et al., 2011).

 

 

칸나비노이드

www.dopza.com

돕자몰

 

우울증 Depression

 

CBD는 동물 모델에서 항우울 효과와 항-불안증 효과를 입증했습니다(de Mello Schier 등 2014) (Zanelati 등 2010).
CBD has demonstrated both antidepressant and anti-anxiety effects in animal models (de Mello Schier, et al., 2014) (Zanelati, et al., 2010).

당뇨병 Diabetes

CBD는 혈류에서의 친-염증성 사이토카인과 비만(non-obese) 쥐에서의 당뇨병 발병률을 현저하게 감소시키는 것으로 나타났습니다(Weiss 등 2006).
CBD has shown to significantly reduce pro-inflammatory cytokines in the bloodstream and the incidence of diabetes in non-obese mice (Weiss, et al., 2006).

 CBD는 또한 질병의 증상을 줄이는데 효과적임이 밝혀졌습니다(Weiss 등 2008).
It’s also been shown to be effective at curtailing the manifestations of the disease (Weiss, et al., 2008).

 연구에 따르면 CBD 치료가 당뇨병성 망막증에서 상당한 보호를 제공한다는 사실도 발견되었습니다(El-Remessy 등 2006).
Research has also found that CBD treatments provide significant protection from diabetic retinopathy (El-Remessy, et al., 2006).

 

 뇌전증 및 발작 장애
Epilepsy and Seizure Disorders

 

CBD는 발작을 줄이거나 심지어 없애는 능력을 보여 주었습니다(Blair, Deshpande & DeLorenzo, 2015) (Rosenberg, Tsien, Whalley & Devinsky, 2015) (Szaflarski & Bebin, 2014) (Devinsky 등 2014).
CBD has demonstrated the ability to reduce or even eliminate seizures (Blair, Deshpande & DeLorenzo, 2015) (Rosenberg, Tsien, Whalley & Devinsky, 2015) (Szaflarski & Bebin, 2014) (Devinsky, et al., 2014).

 또한 칸나비스가 드라베트(Dravet) 증후군, 두세(Doose)  증후군, 레녹스-가스토(Lennox-Gastaut) 증후군과 같은 심각한 소아뇌전증의 치료에 효과적이라는 연구 결과가 있습니다 (Porter & Jacobson, 2013).
Research also finds that cannabis is effective in the treatment of severe pediatric epilepsy disorders like Dravet syndrome, Doose syndrome and Lennox-Gastaut syndrome (Porter & Jacobson, 2013).

 CBD는 뇌전증 어린이에서 수면(53%), 기민성(71%),  기분(63%)을 향상시키는 것으로 나타났습니다(Hussain 등 2015).
CBD has also been shown to improve sleep (53%), alertness (71%), and mood (63%) in epileptic children (Hussain, et al., 2015).

 

 

백혈병
Leukemia

 

CBD는 백혈병 환자가 줄기 세포 또는 골수 이식을 받은 후 발생할 수 있는 합병증을 예방하는 데 도움이 됩니다 (Yeshurun, 등, 2015).
CBD helps prevent complications that can occur after a leukemia patient receives a stem cell or bone marrow transplant (Yeshurun, et al., 2015).

또한 암환자가 전통적 암 치료와 관련된 메스꺼움, 구토,  통증을 관리하고 식욕을 자극하도록 도와주는 것으로 밝혀졌습니다(Guzman, 2003).
In addition, it has been found to help cancer patients manage the nausea, vomiting and pain associated with traditional cancer treatments and to stimulate appetite (Guzman, 2003).

 

편두통
Migraines

 

CBD는 두통과 편두통 등 여러 상태와 관련된 통증을 감소시키는 데 효과적입니다 (Baron, 2015).
CBD is effective at reducing pain associated with a wide variety of conditions, including headache and migraines (Baron, 2015).

 

 

다발성경화증
Multiple Sclerosis

 

CBD는 다발성경화증과 관련된 염증과 싸움으로, 신경을 보호하고 질병 진행을 제한합니다 (Kozela, 등, 2011) (Mecha, 등, 2013).
CBD combats the inflammation associated with multiple sclerosis, therefore providing neuroprotection and limiting the disease’s progression (Kozela, et al, 2011) (Mecha, et al., 2013).

 CBD는 다발성경화증으로 인한 경련을 효과적으로 감소시킵니다 (Collin, 등, 2010).
CBD effectively reduces the spasticity caused by multiple sclerosis (Collin, et al., 2010).

 또한, 다발성경화증과 관련된 신경병성 통증을 감소시킬 수 있는 능력을 보여 주었습니다(Barnes, 2006).
In addition, it has demonstrated the ability to reduce the neuropathic pain associated with multiple sclerosis (Barnes, 2006).

 

 구역질
Nausea

 

연구에 따르면 CBD 등 칸나비노이드는 메스꺼움 증상을 조절하기 어렵고 화학요법 환자에서 예상되는 구역질을 예방하는 데 효과적입니다(Parker, Rock & Limbeer, 2011).
Studies have found that cannabinoids, including CBD contained in cannabis, are effective at treating the more difficult to control symptoms of nausea, as well as preventing anticipatory nausea in chemotherapy patients (Parker, Rock & Limbeer, 2011).

 

 

비만
Obesity

 

CBD는 체중 증가를 현저하게 감소시키고 지질 수준을 감소시키는 것으로 나타났습니다 (Ignatowska-Jankowska, Jankowski & Swiergiel, 2011) (Silvestri, et al., 2015).
CBD has been shown to cause a significant decrease in body weight gain and reduce lipid levels (Ignatowska-Jankowska, Jankowski & Swiergiel, 2011) (Silvestri, et al., 2015).

 

 

통증
Pain

 

CBD는 경련, 두통, 편두통, 기타 급성 통증, 만성통증 질환 등  다양한 병과 관련된 통증 수준을 낮추는데 효과적입니다 (Jensen, Chen, Furnish & Wallace, 2015) (Baron, 2015).
CBD has been shown effective at lowering pain levels associated with a wide variety of conditions, including spasticity, headache, migraines, and other acute pain and chronic pain conditions (Jensen, Chen, Furnish & Wallace, 2015) (Baron, 2015).

 

파킨슨병
Parkinson’s Disease

 

CBD는 신경보호 성질이 있으며 신경세포 미토콘드리아의 건강을 돕고, 따라서 신경퇴화를 예방하는데 도움을 줍니다
(Silva 등 2014)(Zuardi, 2008)(Fernandez-Ruiz 등 2013).
CBD has neuroprotective properties and supports the health of neural cells mitochondria, thus helping to prevent neurodegeneration (da Silva, et al., 2014) (Zuardi, 2008). (Fernandez-Ruiz, et al., 2013).

CBD 치료를 받는 파킨슨병 환자의 삶의 질이 크게 향상되었습니다(Chagas 등 2014).
Significant improvements in well being and quality of life scores were found in Parkinson’s disease patients undergoing CBD treatment (Chagas, et al., 2014).

CBD는 정신병을 앓는 파킨슨병 환자에게 도움이 될 수 있습니다(Zuardi  등 2009).
CBD may help with those Parkinson’s’ disease patients experiencing psychosis (Zuardi, et al., 2009).

 

 

외상후스트레스장애 (PTSD)
Post-Traumatic Stress Disorder (PTSD)

 

CBD와 체내칸나비노이드 체계(ECS)의 칸나비노이드 수용체(CB1과 CB2)의 상호작용은 즐거움을 증가시키고, 기억 과정의 교대를 시작하는 신경전달물질의 방출을 조절합니다 (Betthauser, Piilz, Vollmer, 2015).
CBD’s interaction with the cannabinoid receptors (CB1 and CB2) of the endocannabinoid system modulates the release of neurotransmitter that increases a sense of pleasure and initiates alternation of memory processes (Betthauser, Piilz, Vollmer, 2015).

 CBD는 또한 외상 사건의 연속적 기억을 막을 수 있기 때문에 확장을 강화하고 관련 불안을 줄일 수 있습니다(Akirav, 2013) (Trezza & Campolongo, 2013) (Passie 등 2012).
CBD can also block the continuous retrieval of the traumatic event, thus enhancing its extension and reducing its associated anxiety (Akirav, 2013) (Trezza & Campolongo, 2013) (Passie, et al., 2012).

 

 

조현병    
Schizophrenia

 

CBD는 항-불안증 및 항-향정신성 약물을 함유하고 있습니다.
임상실험에서 CBD로 치료받은 조현병 환자는 CBD가 조현병에 대한 안전하고 내약성이 뛰어난 대체 치료제임을 보여 주었습니다(Zuardi 등 2006) (Leweke 등 2012).
CBD has anxiolytic and antipsychotic properties. Schizophrenia patients treated with CBD in trials have shown that CBD is a safe and well-tolerated alternative treatment for schizophrenia (Zuardi, et al., 2006) (Leweke, et al., 2012).

 

겸상 적혈구 빈혈
Sickle Cell Anemia

 

칸나비노이드는 겸상 적혈구 질환과 관련된 심한 통증을 줄이는데 도움이 되는 것으로 나타났습니다(Kohli, 등, 2010) (Howard 등 2005).
Cannabinoids have shown to be effective at helping curtail the severe pain associated with sickle cell disease (Kohli, et al., 2010) (Howard, et al., 2005).

 

척수 질환
Spinal Cord Disease

 

CBD는 척수질환 및 손상 환자에서 방광조절, 근육경련, 경련을 개선합니다(Wade 등 2003).
CBD improves bladder control, muscle spasms and spasticity in patients with spinal cord diseases and damage (Wade, et al, 2003).

 

척수 부상 Spinal Cord Injuries

 

척수 손상 직후에 관리하면 CBD는 신경보호 반응을 자극하여 손상을 제한합니다(Arevalo-Martin 등 2012).
When administered shortly after a spinal cord injury, CBD stimulates a neuroprotective response to limit damage (Arevalo-Martin, et al., 2012).

 CBD는 척수손상 후 운동 점수를 향상시키는 것으로 나타났습니다 (Kwiatkoski 등 2012).
CBD has shown to improve motor scores following a spinal cord injury (Kwiatkoski, et al, 2012).

 

 

뇌졸중
Stroke

 

뇌졸중 직후 CBD를 투여하면 신경세포와 성상 세포가 손상되지 않도록 보호하여, 기능적, 조직학적, 생화학적, 신경행동 회복이 향상됩니다(Lafuente 등 2011).
Administering CBD shortly after a stroke protects neurons and astrocytes from damage, and therefore leads to improved functional, histological, biochemical, and neurobehavior recovery (Lafuente, et al., 2011).

 

 

외상성 뇌 손상
Traumatic Brain Injury

 

CBD는 신경보호 효능을 제공하고 외상성 뇌손상 후 뇌손상을 제한하는 것으로 나타났습니다 (Castillo, 등, 2010) (Mechoulam & Shohami, 2007) (Pazos, 등, 2013).
CBD has shown to provide a neuroprotective effect and limit brain damage following a traumatic brain injury (Castillo, et al., 2010) (Mechoulam & Shohami, 2007) (Pazos, et al., 2013).

 

References:

Akirav, I. (2013). Targeting the endocannabinoid system to treat haunting traumatic memories. Frontiers in Behavioral Neuroscience, 7, 124. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776936/. Amtmann, D., Weydt, P., Johnson, KL., Jensen, MP. And Carter, GT. (2004). Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care, 21(2), 94-104. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/104990910402100206. Arevalo-Martin, A., Garcia-Ovejero, D., Sierra, Palomares, Y., Paniagua-Torija, B., Gonzalez-Gil, I., Oretega-Gutierrez, S. and Molina-Holgado, E. (2012). Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. PLos One, 7(11), e49057. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496738/. Avraham, Y., Grigoriadis, N., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., and Berry, E. (2011, April). Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. British Journal of Pharmacology, 162(7), 1650-8. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057300/. Barnes, M.P. (2006, April). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opinion on Pharmacotherapy, 7(5), 607-15. Retrieved from http://www.tandfonline.com/doi/full/10.1517/14656566.7.5.607?needAccess=true. Baron, E.P. (2015, June). Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. Headache, 55(6), 885-916. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.12570/full. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardo, A.W., and Crippa, J.A. (2011, May). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219-26. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079847/. Bergamaschi, M.M., Queiroz, R.H., Zuardi, A.W., and Crippa, J.A. (2011, September 1). Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Current Drug Safety, 6(4), 237-49. Retrieved from http://www.eurekaselect.com/75752/article. Betthauser, K., Pilz, J., and Vollmer, LE. (2015, August). Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. American Journal of Health-System Pharmacy, 72(15), 1279-84. Retrieved fromhttp://www.ajhp.org/content/72/15/1279.long. Blair, R.E., Deshpande, L.S., and  DeLorenzo, R.J. (2015, September). Cannabinoids: is there a potential treatment role in epilepsy? Expert Opinion on Pharmacology, 16(13), 1911-4. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845642/. Campbell, V.A., and Gowran, A. (2007, November). Alzheimer’s disease, taking the edge off with cannabinoids? British Journal of Phamacology, 152(5), 655-662. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190031/. Campos, A.C., Ferreira, F.R., and Guimaraes, F.S. (2012, November). Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5Ht1A receptors. Journal of Psychiatric Research, 46(11), 1501-10. Retrieved from http://www.journalofpsychiatricresearch.com/article/S0022-3956(12)00245-2/fulltext. Carter, GT., Abood, ME., Aggarwal, SK and Weiss, MD. (2010). Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. American Journal of Hospice & Palliative Medicine, 27(5), 347-356. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/1049909110369531. Castillo, A., Tolon, M.R., Fernandez-Ruiz, J., Romero, J., Martinez-Orgado, J. (2010, February). The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiology of Disease, 37(2), 434-40. Retrieved from http://www.sciencedirect.com/science/article/pii/S096999610900309X. Chagas, M.H., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., Camilo, M.R., Bergamaschi, M.M., Schenck, C.H., Hallack, J.E., Tumas, V., and Crippa, J.A. (2014, October). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case serious. Journal of Clinical Pharmacy and Therapeutics, 39(5), 564-6. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12179/full. Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., and Crippa, J.A. (2014, November). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology, 29(11), 1088-98. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881114550355. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O’Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. (2010, June). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurological Research, 32(5), 451-9. Retrieved from http://www.tandfonline.com/doi/pdf/10.1179/016164109X12590518685660?needAccess=true.Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simoes, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M.C., McGuire, P.K., Zuardi, A.W., Busatto, G.F., and Hallak, J.E. (2011, January). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 25(1), 121-30. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881110379283. da Silva, V.K., de Freitas, B.S., da Silva Dornelles, A., Nery, L.R., Falavigna, L., Ferreira, R.D., Bogo, M.R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., and Schroder, N. (2014, February). Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. Molecular Neurobiology, 49(1), 222-33. Retrieved from http://link.springer.com/article/10.1007%2Fs12035-013-8514-7. De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B.Y., Scuderi, C., Sarnellil, G., Cuomo, R., Steardo, L., De Man, J.g., and Iuvone, T. (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One, 6(12), e28159. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232190/. de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrion, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., and Silva, A.C. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS & Neurological Disorders Drug Targets, 13(6), 953-60. Retrieved from http://www.eurekaselect.com/122699/article. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Asward, D., Notcutt, W.G., Martinez-Orgado, J., Robson, P.J., Rohrback, B.G., Thiele, E., Whalley, B., and Friedman, D. (2014, June). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707667/. Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., and Lotan, C. (2007, December). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology: Heart and Circulatory Physiology, 293(6), H3602-7. Retrieved from http://ajpheart.physiology.org/content/293/6/H3602.long. Elmes, M.W., Kaczocha, M., Berger, W.T., Leung, K., Ralph, B.P., Wang, L., Sweeney, J.M., Miyauchi, J.T., Tsirka, S.E., Ojima, I., and  Deutsch, D.G. (2015). Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). The Journal of Biological Chemistry, 290(14), 8711–8721. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423662/. El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., and Liou, G.I. (2006, January). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. American Journal of Pathology, 168(1), 235-44. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592672/. Esposito, G., Filippis, D.D., Cirillo, c., Iuvone, t., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., and Steardo, L. (2013, May). Cannabidiol in inflammatory bowel diseases: a brief overview. Phytotherapy Research, 27(5), 633-6. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/ptr.4781/full. Fernandez-Ruiz, J., Sagredo, O., Pazos, M.R., Garcia, C., Pertwee, R., Mechoulam, R., and Martinez-Orgado, J. (2013, February). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323-33. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579248/. Guzman, M. (2003, October). Cannabinoids: potential anticancer agents. Nature Reviews, 3(10), 745-55. Retrieved from http://www.nature.com/nrc/journal/v3/n10/full/nrc1188.html. Howard, J., Anie, KA., Holdcroft, A., Korn, S. and Davies, SC. (2005, October). Cannabis use in sickle cell disease: a questionnaire study. British Journal of Haematology, 131(1), 123-8. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05723.x/full. Hussain, SA., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, JT., and Sankar, R. (2015, June). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy & Behavior, 47, 138-41. Retrieved from http://www.epilepsybehavior.com/article/S1525-5050(15)00157-2/fulltext. Ignatowska-Jankowska, B., Jankowski, M.M., and Swiergiel, A.H. (2011, February 18). Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. Neuroscience Letters, 490(1), 82-4. Retrieved from http://www.sciencedirect.com/science/article/pii/S0304394010015776. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004, April). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. Journal of Neurochemistry, 89(1), 134-41. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2003.02327.x/full. Jensen, B., Chen, J., Furnish, T., and Wallace, M. (2015, October). Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence. Current Pain and Headache Reports, 19(10), 524. Retrieved from http://link.springer.com/article/10.1007%2Fs11916-015-0524-x. Kogan, N. M., Melamed, E., Wasserman, E., Raphael, B., Breuer, A., Stok, K. S., Sondergaard, R., Escudero, A. V., Baraghithy, S., Attar-Namdar, M., Friedlander-Barenboim, S., Mathavan, N., Isaksson, H., Mechoulam, R., Müller, R., Bajayo, A., Gabet, Y. and Bab, I. (2015). Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. Journal of Bone and Mineral Research. doi: 10.1002/jbmr.2513. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2513/full. Kohli, DR., Li, Y., Khasabov, SG., Gupta, P., Kehl, LJ., Ericson, ME., Nguyen, J., Gupta, V., Hebbel, RP., Simone, DA. and Gupta, K. (2010, July 22). Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood, 116(3), 456-65. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913454/. Kozela, E., Lev., N., Kauschansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., and Vogel, Z. (2011, August). Cannabidiol inhibits pathogentic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL-6 mice. British Journal of Pharmacology, 163(7), 1507-19. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165959/. Kwiatkoski, M., Guimaraes, F.S., Del-Bel, E. (2012, April). Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury. Neurotoxicity Research, 21(3), 271-80. Retrieved from http://link.springer.com/article/10.1007%2Fs12640-011-9273-8. Lafuente, H., Alvarez, F.J., Pazos, M.R., Alvarez, A., Rey-Santano, M.C., Mielgo, V., Murgia-Esteve, X., Hilario, E., and Martinez-Orgado, J. (2011, September). Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. Pediatric Research, 70(3), 272-7. Retrieved from http://www.nature.com/pr/journal/v70/n3/full/pr2011171a.html. Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., and Denovan‐Wright, E.M. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology, 172(20), 4790–4805. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621983/. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkotter, J., Hellmich, M, and Koeth, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translation Psychiatry, 2, e94. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/.Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharacologogy and Experimental Therapeutics, 318(3), 1375-87. Retrieved from http://jpet.aspetjournals.org/content/318/3/1375.long. Lim, M.P., Devi, L.A., and Rozenfeld, R. (2011). Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. Cell Death & Disease. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168994/. Maa, E. and Figi, P. (2014, June). The case for medical marijuana in epilepsy. Epilepsia, 55(6), 783-6. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/epi.12610/full. Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America, 97(17), 9561–9566. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16904/. Marcu, J.P., Christian, R.T., Lau, D., Zielinski, A.J., Horowitz, M.P., Lee, J., Pakdel, A., Allison, J., Limbad, C., Moore, D.H., Yount, G.L., Desprez, P.Y, and McAllister, S.D. (2010). Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular Cancer Therapeutics, 9(1), 180–189. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806496/. Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., and de Ceballos, M.L. (2011, June). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Molecular Pharmacology, 79(6), 964-73. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102548/. McAllister, S.D., Christian, R.t., Horowitz, M.P., Garcia, A., and Desprez, P.Y. (2007, November). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular Cancer Therapeutics, 6(11), 2921-7. Retrieved from http://mct.aacrjournals.org/content/6/11/2921.long. McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y, Debs, R.J., Moore, D.H., and Desprez, P.Y. (2011, August). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129(1), 37-47. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410650/. McAllister, S.D., Soroceanu, L., and Desprez, P.Y. (2015, June). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology, 10(2), 255-67. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470774/. Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., and Guaza, C. (2013, November). Cannabidiol provides long-lasting protection against the deletrious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiology of Disease, 59, 141-50. Retrieved from http://www.sciencedirect.com/science/article/pii/S0969996113001939. Mechoulam, R., and Shohami, E. (2007, August). Endocannabinoids and traumatic brain injury. Molecular Neurobiology, 36(1), 68-74. Retrieved from http://link.springer.com/article/10.1007/s12035-007-8008-6. Merrick, J., Lane, B., Sebree, T., Yaksh, T., O’Neill, C., and Banks, S.L. (2016, April). Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid. Cannabis and Cannabinoid Research, 1(1), 102-112. Retrieved from http://online.liebertpub.com/doi/full/10.1089/can.2015.0004. Mukhopadhyay, P., Monanraj, R., and Pacher, P. (2011, May 15). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radical Biology & Medicine, 50(10), 1368-1381. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081988/. Nicholson, A.N., Turner, C., Stone, B.M., and Robson, P.J. (2004, June). Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Journal of Clinical Psychopharmacology, 24(3), 305-13. Retrieved from http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=2004&issue=06000&article=00011&type=abstract. Orellana-Serradell, O., Poblete, CE., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., Llanos, M.N., and Contreras, H.R. (2015, April). Proapoptotic effect of endocannabinoids in prostate cancer cells. Oncology Reports, 33(4), 1599-608. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358087/. Parker, L.A., Rock, EM., and Limbeer, C.L. (2011, August). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411-22. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883513/. Passie, T., Emrich, HM., Karst, M., Brandt, SD. and Halpern, JH. (2012, July-August). Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. Drug Testing and Analysis, 4(7-8), 649-59. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1002/dta.1377/full.Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martinez-Pinilla, E., Moreno, E., Valdizan, E., Romero, J., Pazos, A., Franco, R., Hillard, C.J., Alvarez, F.J., Martinez-Orgado, J. (2013, August). Mechanisms of cannabidiol neuroprotection in hyopoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology, 71, 282-91. Retrieved from http://www.sciencedirect.com/science/article/pii/S0028390813001238. Porter, B.E., and Jacobson, C. (2013, December). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy & Behavior, 29(3), 574-7. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157067/. Rajesh, M., Mukhopadhyay, P., Batkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horvath, B., Mukhopadhyay, B., Becker, L., Hasko, G., Liaudet, L., Wink, D.A., Veves, A., Mechoulam, R., and Pacher, P. (2010, December 14). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. Journal of the American College of Cardiology, 56(25), 2115-25. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026637/. Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., and de Ceballos, M.L. (2005, February). Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience, 25(8), 1904-13. Retrieved from http://www.jneurosci.org/content/25/8/1904.long. Rosenberg, EC., Tsien, RW, Whalley, BJ., and Devinsky, O. (2015, August 18). Cannabinoids and Epilepsy. Neurotherapeutics, 12(4). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604191/. Russo, E., and Guy, G.W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 234-46. Retrieved from http://www.medical-hypotheses.com/article/S0306-9877(05)00431-7/abstract. Silvestri, C., Paris, D., Martella, A., Melck, D., Guadagnino, I., Cawthorne, M., Motta, A., and Di Marzo, V. (2015, June). Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Journal of Heptology, 62(6), 1382-900. Retrieved from http://www.journal-of-hepatology.eu/article/S0168-8278(15)00003-3/fulltext. Szaflarski, JP. and Bebin, EM. (2014, December). Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy & Behavior, 41, 277-82. Retrieved from http://www.epilepsybehavior.com/article/S1525-5050(14)00413-2/fulltext. Takeda, S., Okazaki, H., Ikeda, E., Abe, S., Yoshioka, Y, Watanabe, K., and Aramaki, H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. The Journal of Toxicological Sciences, 39(5), 711-6. Retrieved from https://www.jstage.jst.go.jp/article/jts/39/5/39_711/_pdf. Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A., and Pertwee, R.G. (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British Journal of Pharmacology, 150(5), 613–623. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189767/. Trezza, V., and Campolongo, P. (2013, August 9). The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Frontiers in Behavioral Neuroscience, 7, 100. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739026/. Van Klingeren, B., and Ten Ham, H. (1976). Antibacterial activity of Δ9-­tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek, 42(1-2), 9-12. Retrieved from http://link.springer.com/article/10.1007/BF00399444.Wade, D.T., Robson, P., House, H., Makela, P., and Aram, J. (2003, February). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clinical Rehabilitation, 17(1), 21-9. Retrieved from http://journals.sagepub.com/doi/pdf/10.1191/0269215503cr581oa. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. (2006, March). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39(2), 143-51. Retrieved from http://www.tandfonline.com/doi/full/10.1080/08916930500356674?needAccess=true. Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., and Gallily, R. (2008, January). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology, 54(1), 244-9. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270485/. Weydt, P., Hong, S., Witting, A., Moller, T., Stella, N. and Kliot, M. (2005). Cannabidiol delays symptom onset in SOD1 transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, 6(3), 182-184. Retrieved from http://www.tandfonline.com/doi/abs/10.1080/14660820510030149?journalCode=iafd19. Yeshurun, M., Shpilberg, O., Herscovici, C., Shargian, L., Dreyer, J., Peck, A., Israeli, M., Levy-Assaraf, M., Gruenewald, T., Mechoulam, R., Raanani, P., and Ram, R. (2015, October). Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 21(10), 1770-5. Retrieved from http://www.bbmt.org/article/S1083-8791(15)00375-4/fulltext. Zanelati, T.V., Biojone, C., Moreira, F.A., Guimaraes, F.S., and Joca, S.R. (2010, January). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology, 159(1), 122-8. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823358/.Zhornitsky, S., and Potvin, S. (2012). Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 5(5), 529–552. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763649/. Zuardi, A.W., Shirakawa, I., Finkelfarb, E., and Karniol, I.G. (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology, 76(3), 245-50. Retrieved from https://goo.gl/46mS74. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A., and Guimaraes, F.S. (2006, April). Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research, 39(4), 421-9. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006000400001&lng=en&nrm=iso&tlng=en. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.g., Dursun, S.M., and Tumas, V. (2009, November). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23(8), 979-83. Retrieved from http://journals.sagepub.com/doi/pdf/10.1177/0269881108096519. Zuardi, A.W., (2008, September). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira De Psiquiatria, 30(3), 271-80. Retrieved from http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462008000300015&lng=en&nrm=iso&tlng=en. ]]>

www.dopza.com

돕자몰 - 강아지 고양이 발작 경련 CBD 오일 전문